Literature DB >> 21238516

Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: perspectives and challenges.

Marie-Louise Michel1, Qiang Deng, Maryline Mancini-Bourgine.   

Abstract

The treatment of chronic hepatitis B virus (HBV) infection has greatly improved over the last 10 years, but alternative treatments are still needed. Therapeutic vaccination is a promising new strategy for controlling chronic infection. However, this approach has not been as successful as initially anticipated for chronic hepatitis B. General impairment of the immune responses generated during persistent HBV infection, with exhausted T cells not responding correctly to therapeutic vaccination, is probably responsible for the poor clinical responses observed to date. Intensive research efforts are now focusing on increasing the efficacy of therapeutic vaccination without causing liver disease. Here we describe new approaches to use with therapeutic vaccination, in order to overcome the inhibitory mechanisms impairing immune responses. We also describe innovative strategies for generating functional immune responses and inducing sustained control of this persistent infection.
Copyright © 2011 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21238516     DOI: 10.1016/j.jhep.2010.12.031

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  46 in total

Review 1.  Dissecting the dendritic cell controversy in chronic hepatitis B virus infection.

Authors:  Adam J Gehring; June Ann D'Angelo
Journal:  Cell Mol Immunol       Date:  2014-11-03       Impact factor: 11.530

Review 2.  Antiviral therapies and prospects for a cure of chronic hepatitis B.

Authors:  Fabien Zoulim; David Durantel
Journal:  Cold Spring Harb Perspect Med       Date:  2015-04-01       Impact factor: 6.915

3.  Viral hepatitis. HBV cure--can we pin our hopes on immunotherapy?

Authors:  Hung-Chih Yang; Jia-Horng Kao
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-01-27       Impact factor: 46.802

4.  Analysis of immunological mechanisms exerted by HBsAg-HBIG therapeutic vaccine combined with Adefovir in chronic hepatitis B patients.

Authors:  Chenliang Zhou; Chaofan Li; Guo-Zhong Gong; Shuang Wang; Ji-Ming Zhang; Dao-Zhen Xu; Li-Min Guo; Hong Ren; Min Xu; Qing Xie; Chen Pan; Jie Xu; Zhongyu Hu; Shuang Geng; Xian Zhou; Xianzheng Wang; Xiaoyu Zhou; Haili Mi; Gan Zhao; Wencong Yu; Yu-Mei Wen; Lihua Huang; Xuan-Yi Wang; Bin Wang
Journal:  Hum Vaccin Immunother       Date:  2017-06-30       Impact factor: 3.452

5.  A pregnant patient with a positive hepatitis B surface antigen.

Authors:  Arjmand Rasool Mufti; Nancy Reau
Journal:  Frontline Gastroenterol       Date:  2012-08-31

6.  A prospective study of the efficacy of a combination of autologous dendritic cells, cytokine-induced killer cells, and chemotherapy in advanced non-small cell lung cancer patients.

Authors:  Runbo Zhong; Baohui Han; Hua Zhong
Journal:  Tumour Biol       Date:  2013-09-05

7.  Immunological and antiviral responses after therapeutic DNA immunization in chronic hepatitis B patients efficiently treated by analogues.

Authors:  O Godon; H Fontaine; S Kahi; J F Meritet; D Scott-Algara; S Pol; M L Michel; M Bourgine
Journal:  Mol Ther       Date:  2013-12-05       Impact factor: 11.454

8.  Inhibition of HBV replication by VPS4B and its dominant negative mutant VPS4B-K180Q in vivo.

Authors:  Jianbo Xia; Weipeng Wang; Lei Li; Zhi Liu; Min Liu; Dongliang Yang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-06-09

Review 9.  Vaccine therapies for chronic hepatitis B: can we go further?

Authors:  Yumei Wen; Xuanyi Wang; Bin Wang; Zhenhong Yuan
Journal:  Front Med       Date:  2014-01-24       Impact factor: 4.592

10.  Frangulosid as a novel hepatitis B virus DNA polymerase inhibitor: a virtual screening study.

Authors:  Mokhtar Nosrati; Zahra Shakeran; Zainab Shakeran
Journal:  In Silico Pharmacol       Date:  2018-05-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.